BTAI (BioXcel Therapeutics) Other Current Payables: $0.18 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BTAI BioXcel Therapeutics Inc BTAI
8 GF Score
Price $0.92
GF Value $0.67
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is BioXcel Therapeutics Other Current Payables?

BioXcel Therapeutics BTAI -12.24% 8 Other Current Payables is $0.18 Mil as of Mar. 2026. GuruFocus rates BTAI with a GF Score™ of 8/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 5 warning signs investors should review.

BioXcel Therapeutics's Other Current Payables for the quarter that ended in Mar. 2026 was $0.18 Mil.

BioXcel Therapeutics's quarterly Other Current Payables increased from Sep. 2025 ($0.12 Mil) to Dec. 2025 ($0.14 Mil) and increased from Dec. 2025 ($0.14 Mil) to Mar. 2026 ($0.18 Mil).

BioXcel Therapeutics's annual Other Current Payables declined from Dec. 2023 ($0.11 Mil) to Dec. 2024 ($0.11 Mil) but then increased from Dec. 2024 ($0.11 Mil) to Dec. 2025 ($0.14 Mil).

BioXcel Therapeutics Other Current Payables Related Terms

BioXcel Therapeutics Other Current Payables Historical Data

* Premium members only.

The historical data trend for BioXcel Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioXcel Therapeutics Other Current Payables Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.42 0.11 0.11 0.14

BioXcel Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.12 0.14 0.18
BTAI
8GF Score
BioXcel Therapeutics Inc BTAI
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioXcel Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.18 Mil mean?
BioXcel Therapeutics (BTAI) has a Other Current Payables of $0.18 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on BioXcel Therapeutics and its competitors.
Is BioXcel Therapeutics' Other Current Payables too high?
BioXcel Therapeutics' current Other Current Payables is $0.18 Mil. Overall, BioXcel Therapeutics has a GF Score™ of 8/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Other Current Payables compare to IXHL and SCYX?
BioXcel Therapeutics' Other Current Payables of $0.18 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on BioXcel Therapeutics and its competitors. BioXcel Therapeutics's current Other Current Payables is $0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $0.92 — trading 37.5% above its estimated fair value. The current Other Current Payables is $0.18 Mil. BioXcel Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Other Current Payables is $0.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioXcel Therapeutics (BTAI) Overvalued in 2026?

Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued. The current stock price of $0.92 is trading 37.5% above its estimated GF Value™ of $0.67. GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.

Key valuation signals for BTAI:

  • Other Current Payables: $0.18 Mil
  • GF Value™: $0.67 vs. price of $0.92 (37.5% above fair value)
  • GF Score™: 8/100 with 5 warning signs

No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioXcel Therapeutics Business Description

Other Exchanges BX20:Germany
Address 555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
8GF Score

Get the complete analysis for BTAI

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.92
Price
$0.67
GF Value